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Behçet disease (BD) is a chronic inflammatory multisystem disease characterized by oral and genital ulcers, uveitis, and skin lesions.
Disease etiopathogenesis is still unclear. We aim to elucidate some aspects of BD pathogenesis and to identify specific gene
signatures in peripheral blood cells (PBCs) of patients with active disease using novel gene expression and network analysis. 179
genes were modulated in 10 PBCs of BD patients when compared to 10 healthy donors. Among differentially expressed genes
the top enriched gene function was immune response, characterized by upregulation of Th17-related genes and type I
interferon- (IFN-) inducible genes. Th17 polarization was confirmed by FACS analysis. The transcriptome identified gene
classes (vascular damage, blood coagulation, and inflammation) involved in the pathogenesis of the typical features of BD.
Following network analysis, the resulting interactome showed 5 highly connected regions (clusters) enriched in T and B cell
activation pathways and 2 clusters enriched in type I IFN, JAK/STAT, and TLR signaling pathways, all implicated in
autoimmune diseases. We report here the first combined analysis of the transcriptome and interactome in PBCs of BD patients
in the active stage of disease. This approach generates useful insights in disease pathogenesis and suggests an autoimmune
component in the origin of BD.
1. Introduction
Behçet disease (BD) is a chronic multisystem disease mainly
characterized by mucous-cutaneous lesions such as oral and
genital ulcers, erythema nodosum-like lesions, and papulo-
pustular lesions, and by uveitis. Moreover, manifestations
of vascular, articular, neurologic, urogenital, gastrointestinal,
pulmonary, and cardiac involvement may occur.
BD was first described by Hulusi Behçet in 1937 as a tri-
symptom complex represented by recurrent aphthous sto-
matitis, genital ulcers, and uveitis. The diagnosis of the
disease is still based on clinical criteria since universally
accepted pathognomonic laboratory tests are lacking. An
international study group on Behcet’s disease has recently
revised the criteria for classification/diagnosis of BD [1].
There are sporadic cases of BD all around the world, but
it is most frequently seen along the ancient Silk Route, with a
prevalence of 14–20/100,000 inhabitants. According to epi-
demiological studies, the disease is most prevalent in coun-
tries located between 30 and 45° north latitude through the
Mediterranean Basin, the Middle East and Far East regions
such as China and Japan [2].
The interaction between a complex genetic background
and both innate and adaptive immune systems leads to the
clinical features of the disease. The presence of familiar cases
in 10% of the patients, the particular geographic distribution
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and the high frequency of HLA-B51, a split antigen of HLA-
B5, among a wide range of ethnic populations favours the
role of genetic factors in the pathogenesis of the disease, but
it remains poorly understood [3]. Non-HLA genes also
contribute to the development of BD [3]. Genome-wide asso-
ciation studies have shown that polymorphisms in genes
encoding for cytokines, activator factors, and chemokines
are associated with increased BD susceptibility. Among cyto-
kines, IL-10 polymorphisms cause a reduction of the serum
level of IL-10, an inhibitory cytokine that regulates innate
and adaptive immune responses; on the other hand, IL-23
receptor polymorphism, which reduces its ability to respond
to IL-23 stimulation, is associated with protection from BD
[3–5]. Recent data also reported associations with CCR1,
STAT4, and KLRC4 encoding a chemokine receptor, a tran-
scription factor implicated in IL-12 and IL-23 signaling and a
natural killer receptor, respectively [6, 7]. Moreover, suscep-
tibility genes implicating the innate immune response to
microbial exposure have recently been identified by Immu-
nochip analysis [8].
Increased Th1, CD4+, and CD8+ T cell, γδ+ T cell, and
neutrophil activities were found both in the serum and in
inflamed tissues of BD patients, which suggests that innate
and adaptive immunities are involved together in the patho-
genesis of BD [2, 9]. Similar to other autoimmune disorders,
BD shows Th1-type cytokine profiles. IL-2- and interferon-
(INF-) γ-producing T cells were increased in patients with
active BD, while IL-4-producing T cells were lower than in
controls [10]. Recent findings have shown that Th17 may
play an important role in the pathogenesis of the disease [2,
11]. This hypothesis is supported by the observation of high
IL-21 and IL-17 levels in sera of patients affected by BD with
neurologic involvement [12, 13]. Another study showed that
Th17/Th1 ratio in peripheral blood of patients with BD was
higher than those of healthy controls, whereas the Th1/Th2
and Th17/Th2 ratios were similar among the two groups.
Patients with uveitis or folliculitis had higher Th17/Th1 ratio
compared with patients without these manifestations [14,
15]. Further investigation is required in order to better
understand the role of the immune system in BD and
whether the polarization towards a Th1/Th17 pathway may
play a critical role in BD pathogenesis.
In this study, we used a gene array strategy to identify
transcriptional profiles of PBCs obtained from patients with
active BD. Using this approach, we think we have been able
to shed a new light on some aspects of the disease pathogen-
esis by dissecting different aspects of this complex pathology
in order to better clarify the role of the immune system in BD.
2. Patients and Methods
2.1. Patients. We studied a cohort of 51 patients (16 males
and 35 females, mean age: 37± 11 years) affected by BD,
attending the Unit of Autoimmune Diseases at the University
Hospital in Verona, Italy.
All patients fulfilled the International Criteria for Behçet
Disease (ICBD): oral aphthosis, genital ulcers, and ocular
lesions were each given 2 points, whereas 1 point was
assigned to each of skin lesions, vascular manifestations,
and neurological manifestations. A patient scoring 4 points
or above was classified as having BD [16, 17].
At enrollment, none of the patients had active infections
or was affected by malignancies.
A group of 10 subjects with BD was selected within the
entire cohort of BD patients and utilized for the gene array
study. The clinical features of the patients are reported in
Table 1 that also includes a description of the BD patients
selected for the gene array study.
A written informed consent was obtained from all the
participants of the study. The study was approved by local
Ethical Committee of the Azienda Ospedaliera Universitaria
of Verona, Verona, Italy. All investigations have been
conducted according to the principles expressed in the
Helsinki declaration.
2.2. Gene Array. Blood sample collection was prepared using
PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon,
Switzerland), and total RNA was extracted by following the
manufacturer’s instructions. cRNA preparation, sample
hybridization, and scanning were performed as recom-
mended by the Affymetrix (Affymetrix, Santa Clara, CA,
USA) supplied protocols and by the Cogentech Affymetrix
microarray unit (Campus IFOM IEO, Milan, Italy) using
Human Genome U133A 2.0 (HG-U133A 2.0) GeneChip
(Affymetrix). For gene expression profile analysis, we
followed the methods of Dolcino et al. [18]. Trancripts with
an expression level at least 2.0 fold different in the test sample
versus control sample (p ≤ 0 01) were functionally classified
according to the Gene Ontology (GO) annotations and sub-
mitted to the pathway analysis using the PANTHER expres-
sion analysis tools (http://pantherdb.org/) [19]. The
enrichment of all pathways associated with the differentially
expressed genes compared to the distribution of genes repre-
sented on the Affymetrix HG-U133A microarray was ana-
lyzed, and p values≤ 0.05, calculated by the binomial
statistical test, were considered as significant enrichment.
2.3. Protein-Protein Interaction (PPI) Network Construction
and Network Clustering. The search tool for the retrieval of
interacting genes (STRING version 1.0; http://string-db.org/)
is an online database which includes experimental as well as
predicted interaction information and comprises >1100
completely sequenced organisms [20]. DEGs were directly
mapped to the STRING database for acquiring significant
protein-protein interaction (PPI) pairs from a range of
sources, including data from experimental studies and data
retrieved by text mining and homology searches [21]. PPI
pairs with the combined score of ≥0.7 were retained for the
construction of the PPI network.
The graph-based Markov clustering algorithm (MCL)
allows the visualization of high-flow regions (clusters/mod-
ules) separated by boundaries with no flow, containing gene
products that are expected to be involved in the same (or
similar) biological processes [22].
In order to detect highly connected subgraphs (areas),
the MCL algorithm was applied to the protein interactome
graph.
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Cytoscape software [22] was used to visualize all the
constructed networks.
2.4. PBMCs Isolation. PBMCs were obtained from 30 healthy
donors and 30 patients affected by BD through a density-
gradient centrifugation on Lymphoprep (Nycomed Pharma,
Oslo, NO) at 800×g. Cells were washed twice with PBS
and counted using acridine orange (Thermo Fisher Scien-
tific, Waltham, MA, USA), considering only viable cells for
FACS analyses.
2.5. FACS Analysis. Cell samples were treated by following
the methods of Dolcino et al. [18]. Cells were stimulated over
night with Dynabeads Human T-Activator CD3/CD28
(Life Technologies, Carlsbad, CA, USA). The detection of
IL-17 production was analyzed using the IL-17 Secretion
Assay (Miltenyi Biotec, Bergisch Gladbach), following the
manufacturer’s instruction as described in the methods of
Dolcino et al. [18].
2.6. Real-Time RT-PCR. Total RNA was isolated from PBC
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), fol-
lowing the manufacturer’s instructions. PCR was performed
by following the methods of Dolcino et al. [18]. Predesigned,
gene-specific primers and probe sets for each gene (CCL2,
CXCL2, ICAM1, and IL-8) were obtained from Assay-on-
Demand Gene Expression Products (Applied Biosystems).
2.7. Detection of Soluble Mediators in Sera of BD Patients and
Healthy Controls. Serum levels of TNF alpha, IL-8, CXCL1,
CCL2, CCL3, and CCL20 were detected using commercially
available ELISAkits (Quantikine, R&DSystems,Minneapolis,
MN,USA), according to themanufacturer’s instructions in 51
BD patients when compared to the 30 normal healthy donors.
2.8. Statistical Analysis. Statistical testing was performed
using SPSS Statistics 2 software (IBM, United States). Data
obtained from the analysis of the soluble mediators and from
the analysis of IL-17-positive CD4+ T cells in PBMCs were
analyzed using the Student’s unpaired t-test.
3. Results
3.1. Gene Array Analysis. In order to identify specific gene
signatures typically associated with BD, we compared the
gene expression profiles of 10 PBC samples obtained from
10 individual BD patients with 10 PBC samples obtained
from healthy age- and sex-matched donors.
Table 1: Clinical features of the patients with BD included in the study.
Patients 51 (100%)
Sex
Male 16 (31%)
Female 35 (68%)
Clinical features
Aphthous stomatitis 51 (100%)
Genital ulcers 34 (66%)
Erythema nodosum-like lesions 7 (13%)
Papulopustular lesion 37 (72%)
Uveitis 5 (9%)
Epididymitis 3 (5%)
Neurological symptoms 8 (14%)
Vasculitis 6 (12%)
Joints manifestations 43 (84%)
Gastrointestinal involvement 3 (5%)
Association with HLA-B51 32 (62%)
Patients utilised for gene array study 10 (100%)
Sex
Male 6
Female 4
Clinical features
Aphthous stomatitis 10 (100%)
Genital ulcers 4 (40%)
Erythema nodosum-like lesions 1 (10%)
Papulopustular lesion 8 (80%)
Uveitis 1 (10%)
Epididymitis 0
Neurological symptoms 1 (10%)
Vasculitis 3 (30%)
Joint manifestation 8 (80%)
Gastrointestinal involvement 0
Association with HLA-B51 7 (70%)
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We found that 179 modulated genes complied with the
Bonferroni-corrected p value criterion (p ≤ 0 01) and the fold
change criterion (FC≥2), showing robust and statistically sig-
nificant variation between healthy controls and BD PBC. In
particular, 160 and 19 transcripts resulted to be up- and
downregulated, respectively.
Figure 1(a) is a hierarchical cluster diagram representing
the signal intensity of DEGs across samples; the heat map
shows a different gene expression profile between BD
patients and healthy donors that clearly separates the two sets
of specimens.
Figure 1(b) shows a functional classification of all DEGs
according to the Gene Ontology (GO) terms.
The Gene Ontology analysis showed that the vast major-
ity of the regulated transcripts can be ascribed to biological
processes that may play a role in BD, including inflamma-
tion, immune response, apoptosis, blood coagulation, vascu-
lar damage, and cell proliferation. Table 2 shows a detailed
selection of DEGs within the abovementioned processes.
The table also includes GenBank accession numbers and fold
changes. The complete list of modulated genes can be found
in Supplementary Table 1.
Interestingly, regulated transcripts are distributed in gene
categories that control different biological processes. How-
ever, the functional classes which show the highest enrich-
ment in modulated genes are immune response (71/179)
and inflammation (55/179).
Among genes ascribed to the immune response, twenty
Th17-lymphocyte-related genes were upregulated including
interleukin 6 signal transducer, IL6ST, chemokine (C-C
motif) ligand 20, CCL20, suppressor of cytokine signaling
3, SOCS3, chemokine (C-X-C motif) ligand 1, CXCL1,
chemokine (C-X-C motif) ligand 2, CXCL2, chemokine
(C-X-C motif) ligand 3, CXCL3, inducible T cell costimu-
lator, ICOS, intercellular adhesion molecule 1, ICAM1,
interleukin 8, IL-8, interleukin 1 beta, and IL-1B (see also
Table 2). Some genes involved in B cell activity (CD83
molecule, CD72 molecule, Fc receptor-like 2, FCRL2, and
SAM domain, SH3 domain and nuclear localization signals
1 (SAMSN1)) are modulated in patients’ samples, indicat-
ing a concomitant activation of this lymphocyte cell subset
in BD.
Several upregulated genes play a role in innate immunity
and are expressed in neutrophils (i.e., defensin, alpha 1,
DEFA1, Fc fragment of IgA, receptor, and FCAR), dendritic
cells (i.e., Dab, mitogen-responsive phosphoprotein, and
homolog 2 DAB2), and in macrophages (adaptor-related
protein complex 2, mu 1 subunit, and AP2M1).
In agreement with the typical presence of a marked
inflammatory response in BD, we also observed overex-
pression of several proinflammatory transcripts. The
upregulated genes comprise IL-8, IL-1B, CXCL2, CXCL1,
CXCL3, interleukin 1, alpha (IL-1A), tumor necrosis factor
(TNF), and oxidized low-density lipoprotein (lectin-like)
receptor 1 (OLR1/LOX1).
Remarkably, in these two functional classes, we
observed that a large number of genes are involved in well-
known signaling networks that have been associated with
autoimmune diseases.
These signal cascades include: (1) the interferon-alpha
(IFN-A) pathway also named “type I interferon signature”
[23], (2) the Toll-like receptor (TLR) signaling network,
and (3) the JAK/STAT signaling pathway.
In particular, 9 type I interferon-inducible genes (IFIG)
were upregulated (Table 2), thus showing the presence of
an IFN type I signature, typically present in autoimmune dis-
eases such as systemic lupus erythematosus (SLE), rheuma-
toid arthritis (RA), Crohn’s disease, and Sjogren syndrome
(SS) [24–30].
Twelve DEGs belong to the TLR signaling cascade
(Table 2) which is thought to play a role in the onset of sev-
eral autoimmune diseases and has been also implicated in the
pathogenesis of BD [31–34].
Eight upregulated genes belong to the JAK/STAT signal-
ing pathway, and interestingly, an increased JAK/STAT sig-
naling has been associated with almost every autoimmune
disease [35].
Moreover, activation of the JAK/STAT signaling pathway
has been observed in monocytes and CD4+ T cells of patients
with BD [36].
Several genes involved in apoptosis and/or in apoptosis
regulation were modulated in BD samples including myeloid
cell leukemia sequence 1 (BCL2-related), MCL-1, BCL2-like
11, BCL2L11, immediate early response 3, IER3 and ZFP36
ring finger protein-like 2, and ZFP36L2.
Cell proliferation was also deregulated, and we found
modulation of several transcripts including BTG family,
member 2, BTG2, epiregulin, EREG, proline-rich coiled-coil
2C (PRRC2), phosphatase, tensin homolog pseudogene 1
(PTENP1), and amyloid beta (A4) precursor-like protein 2
(APLP2).
Endothelial dysfunction and altered coagulation are
typical features of BD vasculitis, and consistently with
these aspects of the disease, several genes involved in vas-
cular damage are modulated in BD specimens, including
thrombospondin 1, THBS1; protein S alpha, PROS1; plas-
minogen activator, urokinase receptor, PLAU-UPAR;
thrombomodulin, THBD; and vascular endothelial growth
factor A, VEGFA.
The 179 DEGs were then submitted to a pathway analysis
using the PANTHER expression analysis tool and function-
ally annotated according to canonical pathways. Eight
canonical pathways were found to be significantly overrepre-
sented among the differentially expressed genes, and inflam-
mation was the most enriched pathways, followed by
interleukin signaling, Toll-like receptor signaling, blood
coagulation, T cell activation, apoptosis, angiogenesis, and
the B cell activation pathway (Figure 2).
The modulation of some genes showed by gene array
analysis was validated by Q-PCR (Figure 3).
3.2. PPI Network Analysis. The gene expression profiling of
BD PBC was then complemented by the study of functional
interactions between DEGs’ protein products.
To this aim, an interaction network was constructed
upon the 179 DEGs, using the STRING data mining tool
for retrieving well-documented connections between pro-
teins. The obtained protein-protein interaction (PPI)
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Figure 1: Modulated genes in PBCs of 10 BD patients and their functional classification. Heat map of significantly modulated genes (a). Each
row represents a gene, each column shows the expression of selected genes in each individual sample. Blue-violet indicates genes that are
expressed at lower levels when compared with the mean value of the control subjects, orange-red indicates genes that are expressed at
higher levels when compared to the control means, and yellow indicates genes whose expression levels are similar to the control mean.
Panel (b) shows the functional categorization of BD modulated genes according to GO terms. In the legend, the gene classes are listed in a
clock-wise order starting at the “12 o’clock” position.
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Table 2: Annotated genes differentially expressed in BD PBC versus healthy controls grouped according to their function.
Probe set ID Gene title
Gene
symbol
FC p value
Representative
public ID
Adaptive immune
response
T cell response
204794_at Dual specificity phosphatase 2 DUSP2 2.12 0.001 NM_004418
216248_s_at Nuclear receptor subfamily 4, group A, member 2 NR4A2 5.54 0.012 NM_006186
211861_x_at CD28 molecule CD28 2.00 0.014 AF222343
203547_at CD4 molecule CD4 2.02 0.016 BT019811
217394_at T cell receptor alpha variable 13-1 TRAV13-1 2.53 0.001 AE000521
210439_at Inducible T cell costimulator ICOS 2.26 0.006 AB023135
221331_x_at Cytotoxic T-lymphocyte-associated protein 4 CTLA4 2.13 0.003 NM_005214
211085_s_at Serine/threonine kinase 4
STK4/
MST1
2.14 0.005 Z25430
205456_at CD3e molecule, epsilon (CD3-TCR complex) CD3E 2.11 0.004 NM_000733
208602_x_at CD6 molecule CD6 2.47 <0.001 NM_006725
211302_s_at Phosphodiesterase 4B, cAMP specific PDE4B 3.17 0.004 L20966
218880_at FOS-like antigen 2
FOSL2/
FRA2
3.17 0.005 NM_005253
206360_s_at Suppressor of cytokine signaling 3 SOCS3 2.01 0.001 NM_003955
212079_s_at Lysine- (K-) specific methyltransferase 2A
KMT2A/
MLL1
2.57 0.004 NM_001197104
209722_s_at Serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 2.03 0.001 NM_004155
B cell response
201694_s_at Early growth response 1 EGR1 3.86 0.002 NM_001964
207655_s_at B cell linker BLNK −2.10 <0.001 NM_013314
215925_s_at CD72 molecule CD72 −2.09 0.015 NM_001782
220330_s_at SAM domain, SH3 domain, and nuclear localization signals 1 SAMSN1 2.03 0.006 NM_022136
204440_at CD83 molecule CD83 3.47 NM_004233
221239_s_at Fc receptor-like 2 FCRL2 −2.36 0.001 NM_030764
213810_s_at Akirin 2 AKIRIN2 3.12 <0.001 NM_018064
T/B cell response
216901_s_at IKAROS family zinc finger 1 (Ikaros)
IKZF1/
IKAROS
6.08 <0.001 NM_006060
221092_at IKAROS family zinc finger 3 (Aiolos)
IKZF3/
AIOLOS
3.11 0.006 NM_012481
212249_at Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1 3.19 <0.001 JX133164
Innate immune response
201278_at Dab, mitogen-responsive phosphoprotein, homolog 2 DAB2 −2.17 0.006 NM_032552
205033_s_at Defensin, alpha 1 DEFA1 3.80 0.007 NM_004084
205468_s_at Interferon regulatory factor 5 IRF5 2.01 <0.001 EF064718
M97935_5_at Signal transducer and activator of transcription 1, 91 kDa STAT1 2.26 0.001 GU211347
217199_s_at Signal transducer and activator of transcription 2, 113 kDa STAT2 2.02 0.002 S81491
217502_at Interferon-induced protein with Tetratricopeptide repeats 2 IFIT2 2.00 <0.001 NM_001547
201211_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X 2.25 <0.001 NM_001356
211307_s_at Fc fragment of IgA, receptor for
FCAR/
CD89
5.04 0.004 U43677
212105_s_at DEAH (Asp-Glu-Ala-His) box helicase 9 DHX9 3.82 <0.001 NM_001357
200613_at Adaptor-related protein complex 2, mu 1 subunit AP2M1 2.17 <0.001 NM_004068
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Table 2: Continued.
Probe set ID Gene title
Gene
symbol
FC p value
Representative
public ID
NK cell response
215339_at Natural killer-tumor recognition sequence NKTR 2.15 0.001 NM_005385
211242_x_at
Killer cell immunoglobulin-like receptor, two domains, long
cytoplasmic tail, 4
KIR2DL4 2.00 0.004 AF276292
216552_x_at
Killer cell immunoglobulin-like receptor, two domains, short
cytoplasmic tail, 4
KIR2DS4 2.08 0.002 NM_001281972
209722_s_at Serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 2.03 0.001 NM_004155
Adaptive/innate immune
response
204863_s_at
Interleukin 6 signal transducer (gp130, oncostatin M
receptor)
IL6ST 4.44 0.005 AB102799
211192_s_at CD84 molecule CD84 2.32 0.002 AF054818
213810_s_at Akirin 2 AKIRIN2 3.12 0.001 AW007137
209722_s_at Serpin peptidase inhibitor, clade B (ovalbumin), member 9 SERPINB9 2.03 0.001 NM_004155
221491_x_at Major histocompatibility complex, class II, DR beta 1 HLA-DRB1 2.19 <0.001 U65585
213494_s_at YY1 transcription factor YY1 2.00 0.006 NM_003403
Toll-like receptors
signaling
205067_at Interleukin 1, beta IL-1B 6.32 0.001 NM_000576
206676_at Carcinoembryonic antigen-related cell adhesion molecule 8 CEACAM8 5.07 0.003 M33326
204924_at Toll-like receptor 2 TLR2 2.00 0.015 NM_003264
221060_s_at Toll-like receptor 4 TLR4 2.10 0.001 NM_003266
211027_s_at
Inhibitor of kappa light polypeptide gene enhancer in B cells,
kinase beta
IKBKB/
IKKb
2.33 <0.001 AY663108
213281_at Jun protooncogene JUN/AP1 4.51 0.011 NM_002228
206035_at V-rel reticuloendotheliosis viral oncogene homolog REL/c-REL 2.56 0.005 NM_002908
217738_at Nicotinamide phosphoribosyltransferase NAMPT 2.64 0.008 NM_005746
216450_x_at Heat shock protein 90 kDa beta (Grp94), member 1
HSP90B1/
GP96
3.24 <0.001 NM_003299
214370_at S100 calcium binding protein A8 S100A8 3.85 <0.001 NM_002964
211016_x_at Heat shock 70 kDa protein 4 HSPA4 2.25 <0.001 NM_002154
211622_s_at ADP-ribosylation factor 3 ARF3 2.12 <0.001 M33384
Type I interferon
signaling
205468_s_at Interferon regulatory factor 5 IRF5 2.01 <0.001 EF064718
M97935_5_at Signal transducer and activator of transcription 1, 91 kDa STAT1 2.26 0.001 GU211347
217199_s_at Signal transducer and activator of transcription 2, 113 kDa STAT2 2.02 0.002 S81491
216598_s_at Chemokine (C-C motif) ligand 2 CCL2 2.00 0.002 S69738
210001_s_at Suppressor of cytokine signaling 1 SOCS1 2.16 0.012 AB005043
207433_at Interleukin 10 IL-10 2.16 <0.001 NM_000572
210512_s_at Vascular endothelial growth factor A VEGFA 2.01 0.003 AF022375
217502_at Interferon-induced protein with tetratricopeptide repeats 2 IFIT2 2.00 <0.001 NM_001547
201211_s_at DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X 2.25 <0.001 NM_001356
JAK/STAT signaling
M97935_5_at Signal transducer and activator of transcription 1, 91 kda STAT1 2.26 0.001 GU211347
217199_s_at Signal transducer and activator of transcription 2, 113 kda STAT2 2.02 0.002 S81491
204863_s_at
Interleukin 6 signal transducer
(gp130, oncostatin M receptor)
IL6ST 4.44 0.005 AB102799
207433_at Interleukin 10 IL-10 2.16 <0.001 NM_000572
7Journal of Immunology Research
Table 2: Continued.
Probe set ID Gene title
Gene
symbol
FC p value
Representative
public ID
217489_s_at Interleukin 6 receptor IL6R 2.03 0.011 S72848
212249_at Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) PIK3R1 3.19 <0.001 JX133164
210001_s_at Suppressor of cytokine signaling 1 SOCS1 2.16 0.012 AB005043
206360_s_at Suppressor of cytokine signaling 3 SOCS3 2.01 0.001 NM_003955
Inflammatory response
207113_s_at Tumor necrosis factor TNF 2.00 0.008 NM_000594
211506_s_at Interleukin 8 IL-8 10.44 0.013 AF043337
207433_at Interleukin 10 IL-10 2.16 <0.001 NM_000572
205067_at Interleukin 1, beta IL-1B 6.32 0.001 NM_000576
217489_s_at Interleukin 6 receptor IL6R 2.03 0.011 S72848
209774_x_at Chemokine (C-X-C motif) ligand 2 CXCL2 5.75 0.007 M57731
201939_at Polo-like kinase 2 PLK2 6.20 0.012 NM_006622
204470_at Chemokine (C-X-C motif) ligand 1 CXCL1 4.64 0.003 NM_001511
207850_at Chemokine (C-X-C motif) ligand 3 CXCL3 3.53 0.015 NM_002090
210118_s_at Interleukin 1, alpha IL-1A 3.93 0.001 M15329
203751_x_at Jun D protooncogene JUND 3.39 0.008 NM_005354
216598_s_at Chemokine (C-C motif) ligand 2 CCL2 2.00 0.002 S69738
205476_at Chemokine (C-C motif) ligand 20 CCL20 2.23 0.011 NM_004591
205114_s_at Chemokine (C-C motif) ligand 3 CCL3 2.21 0.007 NM_002983
210001_s_at Suppressor of cytokine signaling 1 SOCS1 2.16 0.012 AB005043
212190_at Serpin peptidase inhibitor, clade e, member 2 SERPINE2 −2.14 0.003 NM_006216
211919_s_at Chemokine (C-X-C motif) receptor 4 CXCR4 2.06 0.008 AF348491
205099_s_at Chemokine (C-C motif) receptor 1 CCR1 2.14 0.002 NM_001295
207075_at NLR family, pyrin domain containing 3 NLRP3 2.15 0.011 NM_004895
203591_s_at Colony-stimulating factor 3 receptor CSF3R 1.89 0.012 NM_000760
215485_s_at Intercellular adhesion molecule 1 ICAM1 2.04 0.015 NM_000201
209701_at Endoplasmic reticulum aminopeptidase 1 ERAP1 2.44 <0.001 NM_016442
216243_s_at Interleukin 1 receptor antagonist IL-1RN 2.26 0.008 NM_173842
202643_s_at Tumor necrosis factor, alpha-induced protein 3 TNFAIP3 2.15 0.012 NM_001270508
201044_x_at Dual specificity phosphatase 1 DUSP1 4.71 0.013 NM_004417
210004_at Oxidized low-density lipoprotein (lectin-like) receptor 1
OLR1/
LOX1
4.13 0.002 AF035776
214370_at S100 calcium binding protein A8 S100A8 3.85 <0.001 AW238654
213281_at Jun protooncogene JUN/AP1 4.51 0.011 NM_002228
216450_x_at Heat shock protein 90 kDa beta (Grp94), member 1
HSP90B1/
GP96
3.24 <0.001 NM_003299
Vascular damage
Blood coagulation
204614_at Serpin peptidase inhibitor, clade B (ovalbumin), member 2 SERPINB2 3.96 0.013 NM_002575
202833_s_at Serpin peptidase inhibitor, clade A, member 1 SERPINA1 2.25 <0.001 NM_000295
207808_s_at Protein S alpha PROS1 −2.16 0.002 NM_000313
201110_s_at Thrombospondin 1 THBS1 5.08 0.001 NM_003246
204713_s_at Coagulation factor V (proaccelerin, labile factor) F5 2.53 0.001 NM_000130
203294_s_at Lectin, mannose binding, 1 LMAN1 2.50 <0.001 U09716
213258_at
Tissue factor pathway inhibitor
(lipoprotein-associated coagulation inhibitor)
TFPI −2.53 0.001 BF511231
203650_at Protein C receptor, endothelial PROCR −2.67 0.001 NM_006404
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network comprised 172 genes (nodes) and 2583 pairs of
interactions (edges) (see Supplementary Figure 1).
When we performed a topological analysis of the PPI net-
work using the Cytoscape software, we found that the num-
ber of interactions in which the products of the 71
“immune response genes” (see Supplementary Table 1) were
involved, accounted for the vast majority (70%) of connec-
tions present in the whole network (1819/2583).
Given the high connectivity (i.e., number of connections)
of the immune response gene products, we decided to
perform an additional network analysis that focused on these
gene products, thinking that they could be more informative.
We found that 55 proteins were linked into a
complex network accounting for 307 pairs of interactions.
Figure 4(a) shows a graphical representation of the
PPI network.
A clustering analysis was then carried out to detect clus-
ters (modules) of proteins to which most of the interactions
converged (“high flow areas”) using the MCL algorithm,
and we identified eight clusters that collectively accounted
for 40 nodes and 242 edges (Figure 4(b)).
We next performed a functional enrichment analysis to
identify association of genes, in each cluster, with different
“GO terms” and pathways.
The significantly enriched categories for each cluster are
shown in Figure 4(c).
Interestingly, five out of eight clusters (CL1, CL5, CL6,
CL7, and CL8) were representative of the adaptive
immune response.
In particular, three clusters (CL1, CL5, and CL6) showed
a statistically significant enrichment in “T cell-related” gene
categories and included several genes typically associated
with T cell-mediated immune responses such as: CD3E,
CD4, CD6, CD28, CTLA4, and DUSP2.
The most enriched GO biological processes (GO-BP) in
these clusters were: “T cell differentiation” and “T cell
Table 2: Continued.
Probe set ID Gene title
Gene
symbol
FC p value
Representative
public ID
Angiogenesis
211924_s_at Plasminogen activator, urokinase receptor
PLAUR/
UPAR
3.42 0.007 NM_002659
207329_at Matrix metallopeptidase 8 (neutrophil collagenase) MMP8 2.42 0.012 NM_002424
210512_s_at Vascular endothelial growth factor A VEGFA 2.01 0.003 AF022375
209959_at Nuclear receptor subfamily 4, group A, member 3
NR4A3/
NOR1
5.69 <0.001 U12767
208751_at N-Ethylmaleimide-sensitive factor attachment protein, alpha NAPA 2.56 0.001 XM_011527436
Vasculitis
203887_s_at Thrombomodulin THBD 2.00 0.015 NM_000361
206157_at Pentraxin 3, long PTX3 2.22 0.001 NM_002852
218880_at FOS-like antigen 2
FOSL2/
FRA2
3.17 0.005 NM_005253
Apoptosis
M97935_5_at Signal transducer and activator of transcription 1, 91 kDa STAT1 2.26 0.001 GU211347
200796_s_at Myeloid cell leukemia sequence 1 (BCL2-related) MCL1 8.02 <0.001 AF118124
200664_s_at DnaJ (Hsp40) homolog, subfamily B, member 1
DNAJB1/
HSP40
2.20 0.010 NM_006145
208536_s_at BCL2-like 11 (apoptosis facilitator) BCL2L11 2.38 0.001 NM_006538
213606_s_at Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA 2.30 <0.001 NM_001185077
219228_at Zinc finger protein 331
ZNF331/
RITA
2.50 0.004 NM_018555
209722_s_at Serpin peptidase inhibitor, clade b (ovalbumin), member 9 SERPINB9 2.03 0.001 NM_004155
201631_s_at Immediate early response 3 IER3 2.85 0.001 NM_003897
201367_s_at ZFP36 ring finger protein-like 2 ZFP36L2 9.07 <0.001 NM_006887
Cell proliferation
201235_s_at BTG family, member 2 BTG2 4.53 <0.001 U72649
205767_at Epiregulin EREG 3.51 0.013 NM_001432
214052_x_at Proline-rich coiled-coil 2C
PRRC2C/
XTP2
3.11 <0.001 NM_015172
208701_at Amyloid beta (A4) precursor-like protein 2 APLP2 2.64 <0.001 NM_001642
217494_s_at Phosphatase and tensin homolog pseudogene 1 PTENP1 3.11 0.001 AF040103
Bold characters indicate TH17-related genes.
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Figure 2: Pathways enrichment of BDmodulated genes. (a) Graphical representation of genes ascribed to the enriched pathways, expressed in
y-axis as percentage of all genes represented on the Affymetrix Human gene chip U133A 2.0 (dark purple bars) or as the percentage of genes
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Figure 3: Real-time RT-PCR of some modulated genes confirms the results of gene array analysis. Genes selected for validation were CCL2,
CXCL2, ICAM1, and IL-8. All the transcripts were increased in BD samples when compared to healthy donors. Relative expression levels were
calculated for each sample after normalization against the housekeeping genes 18s rRNA, beta-actin, and GAPDH. Experiments have been
conducted in triplicates. Housekeeping genes: violet bar: 18s rRNA; yellow bar: beta-actin; and blue bar: GAPDH.
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Figure 4: Network analysis of modulated genes in BD. Panel (a): PPI network of genes involved in immune response; panel (b): clusters
extracted from the PPI network; panel (c): biological processes and pathways enriched in the eight modules.
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activation” (CL1), “T cell receptor signaling pathway” (CL5),
“T cell costimulation”, and “positive regulation of T cell acti-
vation” (CL6). The most enriched pathway was the “T cell
activation pathway” (CL1 and CL5).
Two clusters (CL7 and CL8) included DEGs typically
associated with B cell functions (i.e., CD72). These clusters
were significantly enriched in the GO-BP “B cell differentia-
tion” (CL7) and “B cell activation” (CL7, CL8). Moreover,
the B cell activation pathway was the top enriched pathway
in cluster 7.
Several DEGs involved in the innate immune response
(i.e., HDX9, DDX3X, SOCS3, STAT1, IRF5, IFIT2, and
STAT2) were present in clusters CL2 and CL3. Interestingly,
they were significantly enriched in functions of “positive reg-
ulation of type I interferon production” (CL2) and “type I
interferon signaling pathway” (CL3), further confirming the
presence of a type I interferon signature, typically associated
with several autoimmune diseases. Moreover, genes in cluster
3 were significantly involved with the JAK/STAT signaling
pathway (p = 0 0001) and the TLR signaling pathway (p =
0 0001), both implicated with the development of autoim-
mune diseases [31, 35]. Noteworthy, seven Th17-related
proteins (CD28, CD4, ICOS, CD3E, YY1, TLR4, and IL6ST)
were represented in the abovementioned clusters (CL1, CL3,
CL5, CL6, and CL8). Finally, no significant GO-BP or path-
way was identified in cluster CL4.
3.3. Frequency of IL-17-Positive CD4+ T Cells in PBMCs from
Patients with BD.We assessed by flow cytometry the intracel-
lular expression of the IL-17 cytokine, in PBMCs from 30 BD
patients and from 30 healthy control subjects. We found a
higher amount of IL-17-producing CD4+ T cells among the
PBMCs of patients with BD compared with healthy controls.
The mean values obtained in 30 BD PBMC were 1%
±0.12 versus 0.4% ±0.16 (p < 0 0001) (Figure 5).
3.4. Detection of Soluble Mediators in BD Sera. The gene
expression analysis was complemented by the detection of
some of the corresponding soluble mediators in the sera of
patients with BD. We chose to assess the levels of TNF alpha,
IL-8, CXCL1, CCL2, CCL3, and CCL20. Figure 6 shows
the concentration of these molecules in the sera of the
51 BD patients. All these molecules showed increased
serum levels in BD patients when compared to the 30 nor-
mal healthy donors.
4. Discussion
In this paper, we report a comprehensive study of BD gene
expression profiling where for the first time, a conventional
global gene expression analysis was combined to a gene net-
work analysis of functional interactions between DEGs. We
believe that this integrated approach is likely to generate
insights in the complex molecular pathways that control the
different clinical features of BD.
The first contribution of our study is a detailed investiga-
tion of DEGs in PBCs of BD patients in the attempt to clarify
some aspects of BD pathogenesis.
Indeed, the majority of DEGs analyzed is involved in
biological processes closely connected to the key features
of the disease.
BD is a recurrent inflammatory disease with a multisys-
tem involvement, affecting the vasculature, mucocutaneous
tissues, eyes, joints, gastrointestinal tract, and brain.
Consistently with the strong inflammatory response
typical of BD, DEGs indicate upregulation of a large number
of proinflammatory molecules, including TNF, IL-1, IL-8,
IL-10, CXCL1, CCL2, CCL3, and ICAM1, which can be
detected at increased concentration in sera or plasma of BD
patients when compared to healthy controls. [37–42].
Elevated serum levels of IL-8 are detectable in the active
phase of BD and indicate the presence of vascular involve-
ment [37], whereas high serum levels of CXCL1 correlate
with BD disease activity [39]. Since flares of disease are char-
acterized by neutrophil infiltration around blood vessels fol-
lowing increased chemotaxis of neutrophils [43], it is not
surprising to observe upregulation of CSF3R/GCSFR, which
controls neutrophil functions.
Consistently with the gene array data, serum levels of the
proinflammatory mediators TNF alpha, IL-8, CXCL1, CCL2,
CCL3, and CCL20 were significantly higher in our cohort of
51 BD patients when compared to healthy subjects.
The main histopathological finding in BD is a widespread
vasculitis of blood vessels, arteries, and veins characterized by
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Figure 5: Flow cytometric analysis of CD4+ T cells releasing IL-17 in patients with BD. Panel (a) displays the mean percentage of CD4+ T cells
releasing IL-17 of 30 healthy donors and 30 BD patients. PBMCs were stimulated over night with anti-CD3/CD28-coated beads. Panel (b)
shows a representative experiment ((A) normal subjects (NS); (B) BD patients).
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myointimal proliferation, fibrosis, and thrombus formation
leading to tissue ischemia [44]. Occlusion of the vascular
lumen creates a hypoxic milieu that effectively can induce
new vessel formation. Angiogenesis can further stimulate
inflammation since new born endothelial cells release che-
moattractive mediators for leukocytes and express adhesion
molecules [44]. Several DEGs play a role in angiogenesis,
and the highest level of induction was observed for NOR1
(also named NR4A3), a gene expressed in developing neoin-
tima that promotes endothelial survival and proliferation,
acting as a transcription factor in vascular development
[45]. DEGs also showed upregulation of NAPA, known to
induce VE-cadherin localization at endothelial junctions
and regulate barrier function [46]. Interestingly, soluble
VE-cadherins may be increased in the sera of BD patients
[47]. Another upregulated transcript was the gene encoding
for UPAR, expressed in several cell types including mono-
cytes, neutrophils, activated T lymphocytes, macrophages,
and endothelial cells. Indeed, high levels of the soluble
form of UPAR have been detected in the plasma of BD
patients [48].
Other genes, typically associated with the vasculitic
process, were overexpressed in our array including THBD
and PTX3. THBD can be detected at higher levels in sera
of BD patients compared with healthy controls, and it is
associated with the skin pathergy test, considered as a use-
ful test for BD diagnosis. PTX3, an acute-phase reactant
produced at sites of active vasculitis, is an indicator of
active small vessel vasculitis [49].
Defects in blood coagulation and fibrinolysis have been
described in patients with BD with or without thrombosis,
and accordingly, we found downregulation of genes encod-
ing for proteins that have an anticoagulant effect (i.e., TFPI,
PROS1, and PROCR/EPCR) and upregulation of transcripts
which promote the coagulation process (including THBS1,
F5, and LMAN1).
Several DEGs indicate an altered apoptotic process with
up- or downregulation of several apoptosis-related genes.
Endothelial cell apoptosis which plays a pivotal role in vascu-
lar damage and autoantibodies which are able to induce
endothelial cell apoptosis have been reported in BD [50]. In
BD, an altered apoptosis has been described also in other cell
subsets, that is, neutrophils and lymphocytes. Indeed, neu-
trophil apoptosis is reduced in the remission phase of uveitis
and is restored in the active phase [51], whereas T lympho-
cytes are resistant to Fas-mediated apoptosis in BD with
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Figure 6: Serum levels of selected soluble mediators in BD patients and in normal subjects. The histograms represent the mean of the results
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active uveitis [52]. On the contrary, an excessive expression
of FasL on skin-infiltrating lymphocytes and the presence
of apoptotic cells in the skin lesions have been also reported
[53], suggesting that lymphocytes expressing increased levels
of FasL may have a role in the development of BD skin
lesions. Among genes that control cell proliferation, we
observed overexpression of the gene EREG1, which plays an
autocrine role in the proliferation of corneal epithelial cells
[54], and APLP2 gene, involved in corneal epithelial wound
healing [55]. In this regard, it is worthwhile mentioning that
keratitis can be one of the ocular manifestations of BD.
Several aspects of BD are typical of an immune-mediated
disease, but whether BD is an autoimmune or an autoinflam-
matory disease is still debated. A great number of DEGs
(71/179) are involved in the immune response, and themajor-
ity of these genes can be ascribed to the adaptive immune
response. In particular, DEGs indicate a T cell response with
a prevailing upregulation of many TH17-related genes.
In this regard, it is worthwhile mentioning that Th17 cells
have been associated with the pathogenesis of several auto-
immune diseases including psoriasis, RA, and SLE [56–58].
Noteworthy, the involvement of this T cell subset in the path-
ogenesis of BD has been suggested, since Th17-related cyto-
kines are considerably increased in BD and peripheral
blood Th17/Th1 ratio is significantly higher in patients with
active BD compared to healthy controls [11].
To further validate our data on overexpression of the
Th17 pathway in our cohort of patients, we analyzed the
presence of IL-17-producing CD4+ T cells and found a signif-
icantly increased percentage of these cells in PBCs of patients
with BD when compared with healthy donors.
Among DEGs regulating B cell responses, we observed
overexpression of SAMSN1, a transcript induced upon B cell
activation [59], and EGR1, involved in the differentiation
program of B cells into plasma cells, whereas the inhibitory
receptor CD72 that downmodulates B cell receptor (BCR)
signaling was downregulated. All together, these data indi-
cate the activation of the B cell immune response and (auto)-
antibody production suggesting a possible role of these cells
in BD pathogenesis.
Other genes associated with the adaptive immune
response include ICOS, SOCS3, and HLA-DRB1. Interest-
ingly, a high expression of ICOS on CD4+ T cells has been
described in BD patients with active uveitis, suggesting a role
in the pathogenesis of uveitis, possibly through upregulation
of IFN-g, IL-17, and TNF [60].
An increased expression of SOCS3, a regulator of the
JAK/STAT pathway of cytokine induction, has been
observed in all patients with BD irrespective of disease activ-
ity [61], and polymorphisms of HLA-DRB1 alleles have been
associated with BD [62].
In addition, it is worthwhile mentioning that DEGs of
the adaptive immune response include transcripts already
associated with the development of autoimmune diseases,
including CTLA4, MST1, CD6, and the abovementioned
SOCS3 [63–66].
We observed that several upregulated genes, including
IRF5, IFIT2, DDX3X, STAT1, and STAT2 participate to type
I interferon and JAK/STAT signaling pathways.
As already mentioned, type I interferon signaling is asso-
ciated with autoimmune diseases including SLE, RA, Sjog-
ren’s syndrome, and Crohn’s disease [24–30].
In this regard, the copresence of type I IFN signaling and
Th17-related genes suggests an autoimmune component in
the origin of BD, since a synergy between IFN and Th17 path-
ways is commonly involved in autoimmunity [24–30, 67–69].
Moreover, the JAK/STAT signaling is activated in BD [36]
and this pathway has been associated with the development of
systemic autoimmune diseases such as SLE and RA [70].
Our dataset indicates also the overexpression of several
genes belonging to the TLR pathway. Growing body of evi-
dence suggests the association between TLRs and autoimmu-
nity. Indeed, the expression of TLRs in B cells is required for
the synthesis of most of the SLE-associated autoantibodies
[71]. Moreover, in RA, extracellular ligands can enhance
the production of the proinflammatory mediators IL6 and
IL-17 in human synoviocytes and in PBCs [72]. In addition,
in systemic sclerosis activation of TLR4 on the surface of
fibroblasts contributes to the upregulation of profibrotic che-
mokines [73]. Finally, stimulation of TLR2 induces the pro-
duction of IL-23 and IL-17 cytokines from the PBCs of
patients affected by Sjogren’s syndrome [74].
TLR2 and TLR4 have been shown to be overexpressed in
PBCs from patients with eye involvement [72] and in buccal
mucosal biopsies and in PBCs obtained from patients with
flare of the disease [32]. Noteworthy, both TLR2 and TLR4
were upregulated in our array, in accordance with the above
reported data [32, 72].
Pathway analysis may help to elucidate the pathogenesis
of complex or multifactorial diseases, such as BD, that are
often caused by a mixture of abnormalities of correlated tran-
scripts or biological pathways [75]. To this aim, we mapped
our DEGs onto canonical pathways to identify signaling cas-
cades which were overrepresented in our dataset.
Interestingly, pathway enrichment analysis revealed that
inflammation, IL, TLR, blood coagulation, T cell activation,
apoptosis, angiogenesis, and B cell activation signaling path-
ways were the most enriched in BD transcriptoma, further
confirming their crucial role in the disease pathogenesis.
Thanks to our global analysis we have identified modu-
lated genes involved in biological processes that could reca-
pitulate most of the typical features of BD. Indeed, the
majority of DEGs were involved in immune response and
inflammation; moreover, we observed the activation of path-
ways (i.e., JAK/STAT and TLRs) and the presence of signa-
tures (i.e., type I interferon and TH17 cell) typically
associated with an autoimmune response, thus suggesting
an autoimmune component in the origin of BD.
We carried our analysis in order to highlight key DEGs
functionally collaborating in networks that could be involved
in the disease onset and progression.
Indeed, in the second part of our study, instead of looking
at single component of biological processes, we aim to study
the interactions among the protein products of DEGs by a
network analysis.
A network representation is an intriguing way to study
the complex dynamic of disease-associated molecular inter-
actions, and in this perspective, disorders can be considered
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in view of disturbances of molecular networks [76]. Interest-
ingly, we observed that the protein products of genes ascribed
to the immune response showed the highest degree of con-
nectivity in the whole network of DEGs products, thus indi-
cating a preeminent role of this gene category in driving the
global gene expression profiles in BD pathogenesis. Then,
we focused our attention on the PPI network specifically
obtained from the immune response gene products, since it
has been described that deregulation of genes, encoding for
highly interactive proteins, interferes with physiological
processes and that molecules involved in diseases develop-
ment show a high attitude to interact with each other [77].
The clustering analysis of this sub-network helped us to
further prioritize deregulated gene products that were placed
in “highest connectivity areas” (clusters) of the network,
where the hubs of biological process regulation are usually
positioned [78].
In most of the clusters, we found an enrichment in
molecular pathways of B and T cell-mediated adaptive
immune response, thus suggesting a leading role of the
adaptive immunity in the pathogenesis of BD. Moreover,
DEGs in these classes included genes associated with the
Th17 cell response.
Interestingly, we also observed that the molecules present
in the few clusters enriched in innate immune response were
involved in molecular signalings known to play a role in
autoimmune diseases including JAK/STAT, TLRs, and type
I interferon signaling.
These findings support that the disease may be sustained
by an autoimmune process and are not in contrast with the
hypothesis of an autoinflammatory component in the origin
of BD.
The network analysis emphasizes the crucial role played
by the molecular pathways emerged from our first global
gene expression study in BD pathogenesis. Indeed, the mole-
cules that participate to these signaling pathways are concen-
trated in areas (clusters) of the whole network that display
the highest density of connection between genes, thus indi-
cating their prominent role in the disease.
Through this analysis, we believe that we could identify
pathogenically meaningful interactions that would have been
hidden in the whole native dataset and that may be strongly
associated with BD. Moreover, we provide evidence, at least
at a level of gene expression, that BD may have an autoim-
mune origin.
Finally, we believe that our data can provide a deeper
insight into BD pathogenesis, highlighting crucial molecular
pathways including IL-17, IL-6, and JAK/STAT pathways
that may be targeted by biological drugs and by novel thera-
peutical strategies.
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